Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 2, 2009

Cenix to Conduct RNAi-Based Target Discovery for Boehringer Ingelheim

  • Cenix BioScience will help Boehringer Ingelheim discover novel therapeutic drug targets. The firm will combine high-throughput applications of RNAi-based gene silencing with high-content phenotypic analyses in what will be a genome-scale screen using cultured human cells.

    Multiparametric microscopy-based assays developed by Cenix using the Cellenger image analysis platform from Munich-based Definiens, will be used to complement Boehringer Ingelheim’s assays to generate insights into the cellular functions and loss-of-function phenotypes of analyzed genes.

    Such RNAi datasets offer a highly predictive and cost-effective basis for mining the human genome to discover and prioritize targets for therapeutic drug development in a wide range of disease fields, according to Cenix.

    ---

     



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »